196 related articles for article (PubMed ID: 27239256)
1. Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a.
Li MH; Xie Y; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Hu LP; Hua WH; Song SJ; Zhang SF; Cheng J; Xu DZ
World J Hepatol; 2016 May; 8(15):637-43. PubMed ID: 27239256
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
[TBL] [Abstract][Full Text] [Related]
3. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
4. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study.
Chan HLY; Chan FWS; Hui AJ; Li MKK; Chan KH; Wong GLH; Loo CK; Chim AML; Tse CH; Wong VWS
J Viral Hepat; 2019 Jan; 26(1):126-135. PubMed ID: 30187604
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
6. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
7. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.
Cao Z; Liu Y; Ma L; Lu J; Jin Y; Ren S; He Z; Shen C; Chen X
Hepatology; 2017 Oct; 66(4):1058-1066. PubMed ID: 28407271
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
Gish RG; Lau DT; Schmid P; Perrillo R
Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
[TBL] [Abstract][Full Text] [Related]
10. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Yu ML; Lee CM; Chuang WL; Lu SN; Dai CY; Huang JF; Lin ZY; Hu TH; Chen CH; Hung CH; Wang JH; Chen CL; Kao JH; Lai MY; Liu CH; Su TH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Chen PJ; Liu CJ; Chen DS
J Infect Dis; 2010 Jul; 202(1):86-92. PubMed ID: 20482252
[TBL] [Abstract][Full Text] [Related]
11. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
Hu P; Shang J; Zhang WH; Gong GZ; Li YG; Chen XY; Jiang JN; Xie Q; Dou XG; Sun YT; Li YF; Liu YX; Liu GZ; Ma DW; Chi XL; Tang H; Li XO; Xie Y; Chen XP; Jiang JJ; Zha P; Hou JL; Gao ZL; Fan HM; Ding JG; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2018 Oct; 26(10):756-764. PubMed ID: 30481882
[No Abstract] [Full Text] [Related]
12. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
13. Role of hepatitis B surface antigen (HBsAg) in identifying true inactive HBsAg carriers infected with genotype C hepatitis B virus.
Yim SY; Um SH; Jung JY; Seo YS; Yim HJ; Ryu HS; Chun HJ; Jeen YT; Kim CD; Keum B; Lee HS
J Clin Gastroenterol; 2014 Feb; 48(2):166-71. PubMed ID: 24045280
[TBL] [Abstract][Full Text] [Related]
14. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
15. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study.
Hu P; Shang J; Zhang W; Gong G; Li Y; Chen X; Jiang J; Xie Q; Dou X; Sun Y; Li Y; Liu Y; Liu G; Mao D; Chi X; Tang H; Li X; Xie Y; Chen X; Jiang J; Zhao P; Hou J; Gao Z; Fan H; Ding J; Zhang D; Ren H
J Clin Transl Hepatol; 2018 Mar; 6(1):25-34. PubMed ID: 29577029
[No Abstract] [Full Text] [Related]
16. Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up.
Brouwer WP; Chan HL; Brunetto MR; Martinot-Peignoux M; Arends P; Cornberg M; Cherubini B; Thompson AJ; Liaw YF; Marcellin P; Janssen HL; Hansen BE;
Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1481-1489.e5. PubMed ID: 26872398
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers.
Huang Y; Qi M; Liao C; Xun J; Zou J; Huang H; Long LY; Chen J; Fan X; Chen R
Infect Dis Ther; 2021 Dec; 10(4):2323-2331. PubMed ID: 34350562
[TBL] [Abstract][Full Text] [Related]
18. Serum HBsAg levels during peginterferon α-2a treatment with or without thymosin α-1 in HBeAg-positive chronic hepatitis B patients.
Song EY; Shin Y; Roh EY; Sue S; Park MH; Kim BH; Kim W; Yoon JH; Lee YJ; Park SJ; Jung EU; Lee JH; Myung SJ; Kim YJ; Lee HS
J Med Virol; 2011 Jan; 83(1):88-94. PubMed ID: 21108343
[TBL] [Abstract][Full Text] [Related]
19. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients.
Piratvisuth T; Marcellin P; Popescu M; Kapprell HP; Rothe V; Lu ZM
Hepatol Int; 2013 Jun; 7(2):429-36. PubMed ID: 21701902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
